The Stem Cell Decision Greeted Cautiously by Research Communitygreenspun.com : LUSENET : Unk's Wild Wild West : One Thread |
"Date" ="2001-08-10"Kaiser Daily Reproductive Health Report Friday, August 10, 2001
The Stem Cell DecisionBush's Decision Greeted Cautiously by Research Community; Many Express Doubt Over Number of Available Cell Lines
President Bush's decision last night to allow federal funding for research on stem cells already extracted from embryos was greeted as a step forward for the research, but as a "baby step, rather than a giant leap, for medical research," the New York Times reports (Stolberg, New York Times, 8/10). Cell lines are "genetically identical colon[ies] of cells that can replicate indefinitely." In stem cell research practices, a parent cell is derived from a human embryo and then replicates itself in a petri dish to create the colony. Bush declared that he will allow federal funding for research on embryonic stem cells derived from 60 existing cell lines, a figure that surprised many in the research community. "The president seems to have information far different from that of the bulk of the medical community," Dr. Michael Soules, president of the American Society of Reproductive Medicine, said, adding that the society was "only aware of a very small number of stem cell-derived tissue lines and cannot confirm the existence of the large number the president mentioned in his speech" (Hall, San Francisco Chronicle, 8/10). Fewer than 10 lines have been reported in scientific journals and another 10 may have been "described" at scientific forums; an NIH report earlier this summer estimated that perhaps 30 lines existed (Weiss, Washington Post, 8/10). According to a senior Bush adviser, the president had "grown frustrated with vague estimates on how many stem cell lines exist" and asked policy adviser Jay Lefkowitz to request that the NIH determine the actual number (Friend, USA Today, 8/10). The determination that there are 60 lines resulted from NIH officials "calling around the world to talk to researchers." Various lines have been derived in the United States, Austria, India, Israel, Singapore and Sweden, according to another senior administration official, and represent a "diverse genetic and ethnic pool."
Quality Control
Many researchers also questioned whether all of the lines reportedly available would prove useful for research. Cell lines have a "precarious existence" and are liable to "'crash' at any time, disappearing into a shriveled gelatinous mess beyond hope of resuscitation," the Washington Post reports. Of the six cell lines created by Geron Inc., the biotech firm that has funded most American research on embryonic stem cells, only two have been "deemed sufficiently stable and useful to be distributed to stem cell scientists." Furthermore, even 60 cell lines would be "woefully short of representing the genetic diversity of a nation of 200 million Americans, not to mention the rest of the world," Dan Perry, president of the Alliance for Aging Research, noted. Cell lines also have "subtle genetic differences" and those differences "can affect how they behave and what they can teach," the Post reports (Washington Post, 8/10). Dr. Harold Varmus, head of the New York-based Memorial Sloan-Kettering Cancer Center and former director of the NIH, said that the limited number of lines "would be a very poor investment federally, and a very cruel investment if we ended up with knowledge of how to make differentiated cells to treat people and then we were stuck" because of a lack of cell lines (New York Times, 8/10). Gail Martin, the University of California-San Francisco researcher who "laid the groundwork" for human embryonic stem cell research by first isolating stem cells in mice, said that limiting the number of cell lines "puts restrictions on what's going to be possible," and added that "[h]aving a big pot" of cells available was a "very big plus" to her early research (Torassa, San Francisco Chronicle, 8/10). Timothy McCaffrey, an associate professor of biochemistry and molecular biology at George Washington University Medical Center, called Bush's decision to limit the number of cell lines made available "quite ... fair," adding, "Obviously, as a scientist, you want as few restrictions on your work as possible. But this doesn't disable the field at all. Compared with being unable to use federal funds, period, for stem cell research, this is a big step forward" (San Francisco Chronicle, 8/10). It is unclear whether the cell lines Bush mentioned will have to meet ethical guidelines established by the National Bioethics Advisory Commission and the NIH. Those guidelines "explicit[ly]" require that "informed consent" must be obtained from the couples that created the embryos for in vitro fertilization treatments before they can be used for research (Friend, USA Today, 8/10). James Thomson, the University of Wisconsin researcher who first isolated human embryonic stem cells, said the lines derived from his work do not meet those standards, but added that he was "prepared to produce additional lines ... that did" (Lane, Newsday, 8/10).The Effect on Biotech
Bush's decision "will do little to help or harm most biotech firms in the short run," the San Francisco Chronicle reports. However, "over time, his tepid support could drive research abroad and slow the pace of new discoveries." There are only a "handful" of companies are currently conducting stem cell research in the United States and it will be years before research will "yield discoveries with commercial importance." But many researchers were "concerned" that limiting the number of cell lines available in the United States will "let other nations tale the lead" on the research. "We saw this in the late 1970s when the United States didn't allow cloning to be done on pathogens," allowing researchers in Europe to "t[ake] the lead" on research of diseases such as hepatitis B, Ed Penhoet, co-founder of Chiron Corp. and dean of public health at the University of California-Berkeley, said. Stem cell research is already permissible in Great Britain, Japan, Israel and parts of Australia (Abate, San Francisco Chronicle, 8/10). The fact that the majority of cell lines in the United States are controlled by a few companies is also troublesome to some researchers. Geron, which funded Thomson's work, controls many of the lines and "can effectively lay claim to anything commercial that arises from those cells," the Boston Globe reports. "You have to agree to their conditions, which most researchers find unacceptable. We would be de facto reporting to a company on the research we want to do," Melton explained. But Geron CEO Thomas Okrama said his company has "no desire to constrain research." However, Geron "will defend its intellectual property rights," he said, adding "Patents are what patents are. We funded the work, we have the rights" (Shadid, Boston Globe, 8/10). Michael West, CEO of Massachusetts-based Advanced Cell Technology, Geron's chief competitor, said the stem cell debate is already giving way to the next issue: cloning. "Stem cells will be history. This will shift the fight to nuclear transfer," he said (San Francisco Chronicle, 8/10). Advanced Cell is attempting to derive stem cells by taking human eggs, removing their DNA and replacing it with genetic material from a mature adult skin cell to create what West calls an "ovumsum." This process has yet to create a viable stem cell (Elias, AP/Baltimore Sun, 7/16).Bush's Position on Stem Cells 'Left Liberals Unsatisfied, Brought Accusations from Conservatives,' Washington Post Reports
While President Bush hoped that his "measured" decision last night to allow limited federal funding of embryonic stem cell research would "mute criticism," the Washington Post reports that the decision "left liberals unsatisfied" and "brought accusations from conservatives" that the president "set the country on a 'slippery slope' toward the killing of embryos for study" (Milbank, Washington Post, 8/10). Bush faced a "no-win situation" on one of the "most complex issues -- both politically and ethically" -- that he has addressed, the AP/Richmond Times-Dispatch reports (AP/Richmond Times-Dispatch, 8/10). Although Bush aides said that "political considerations" had "no place" in the decision, the New York Times reports that the decision will have "enormous political ramifications" for the president. The White House considered the political "pluses and minuses" before Bush announced his decision, but the "arithmetic most favorable to the president was never clear" (Bruni, New York Times, 8/10). Cox News Service/Contra Costa Times reports that Bush's "personal anguish" over the decision "softened the criticism" from opponents of embryonic stem cell research and "could shield the president from serious political backlash" (Shepard, Cox News Service/Contra Costa Times, 8/10).
Conservative Schism
According to the Washington Times, Bush's decision has "split" social conservatives and abortion-rights opponents (Curl, Washington Times, 8/10). The AP/Richmond Times-Dispatch reports that Republicans "are hardly in agreement" over the issue (AP/Richmond Times-Dispatch, 8/10). The New York Times reports that many Republicans expressed "relief" or "resignation" about Bush's decision (Bruni, New York Times, 8/10). However, leading up to the announcement, some social conservatives said that the decision "could permanently damage Bush" and leave him a "one-term president" (AP/Richmond Times-Dispatch, 8/10).Move to the Middle?
During his address last night, Bush "wended his way to his relatively narrow decision, leaving himself future wiggle room." Several analysts "wondered" if he "laid the groundwork" for support of future "congressional authorization" of the destruction of frozen embryos in fertility clinics. In addition, Bush "did not take a clear position" on "whether an embryo is a human life," the New York Times reports (Bruni, New York Times, 8/10). The address may represent a sign that Bush is "returning to the more moderate 'compassionate conservative' image he built" during his presidential campaign, but according to the Washington Post, it is "far too soon to tell" whether the decision marks a "real shift" by Bush. Few analysts predict an "outright rift" with social conservatives but expect the president "to be pulled back and forth between moderate exigencies and conservative instincts." Although Bush's decision "displeased" many religious conservatives, he "risked alienating moderate voters" by banning federal funding for embryonic stem cell research. Republican strategists predicted that Bush "will be hurt less by dispiriting conservatives than by alienating moderates" (Milbank, Washington Post, 8/10). According to some Republicans, Bush "could afford to make that move because he had placated social conservatives" with his decision to ban federal funding for international groups that use their own funds to offer counseling on abortion (Bruni, New York Times, 8/10). Many conservatives had feared "much broader" federal funding for embryonic stem cell research, the New York Times reports (Toner, New York Times, 8/10).On Capitol Hill
Bush's decision also "virtually guarantees" that the "emotional debate" over the stem cell research issue will "continue on Capitol Hill," and legislative "showdowns appear inevitable" USA Today reports. Lawmakers have introduced a number of bills that would expand embryonic stem cell research "beyond what the president has proposed," and this fall, Congress will set the federal budget for science and medical research (Kiely/Lee, USA Today, 8/10). In addition, the Washington Post reports that new legislation "may arise in the light of Bush's announcement" and that lawmakers "may find it difficult to break their five-year-old habit" of attaching an amendment to the HHS appropriations bill that limits funding for embryo research (Weiss, Washington Post, 8/10). Each year since 1996, Congress has placed a ban on federal funding that "involves the destruction of human embryos" (USA Today, 8/10). NPR reports that majorities in both the House and Senate have expressed support for federal funding of the research (Rovner, "Morning Edition," NPR, 8/10). However, Congressional Quarterly reports that Bush's decision "is likely to be the last word for now" on the issue, noting that although the debate has "spurred hearings, bills and lawsuits," neither supporters nor opponents of federal funding "can muster enough votes to override a presidential veto" (Goldreich, Congressional Quarterly, 8/9). Still, Jim Langevin D-R.I.), a quadriplegic, said that Bush "will have to revisit his decision" when researchers find that "more stem cells are needed" (USA Today, 8/10).Bill Summaries
Some of the bills related to embryonic stem cell research that lawmakers have introduced this year include:
- S 723: Sen. Arlen Specter (R-Pa.) has introduced a bill that would allow federally funded research on stem cells removed from fertilized eggs already set for destruction in private fertility clinics (Congressional Quarterly, 8/9). In the House, Rep. Jim McDermott (D-Wash.) has proposed similar legislation ( HR 2059) (HR 2059 text, 6/5).
- HR 2096: Rep. Chris Smith (R-N.J.) has introduced a bill that would establish a National Stem Cell Donor Bank that would use stem cells from "ethically responsible" sources, such as placentas and umbilical cords (USA Today, 8/10). Sens. John Ensign (R-Nev.) and Sam Brownback (R-Kan.) have offered a similar bill ( S 1349) in the Senate (S 1349 text, 8/3).
- HR 2747: Rep. Diana DeGette (D-Colo.) and Jim Ramstad (R-Minn.) have introduced a bill that would require implementation of the "NIH Guidelines for Research Using Human Pluripotent Cells" (HR 2747 text, 8/2).